M. Weyant
Papers
1
Total Citations
35
H-Index
1
About
M. Weyant is a leading translational researcher in thoracic oncology, whose work centers on the use of circulating tumour DNA (ctDNA) as a dynamic biomarker for lung cancer treatment response. Their most notable contribution comes from a landmark 2021 study, which demonstrated that real-time ctDNA monitoring during neoadjuvant atezolizumab therapy and subsequent surgery can predict patient outcomes in non-small cell lung cancer (NSCLC). This work, cited over 35 times, has helped establish ctDNA kinetics as a powerful tool for guiding immunotherapy decisions and assessing minimal residual disease. Weyant’s research bridges the gap between liquid biopsy technology and clinical practice, offering a non-invasive window into tumour behaviour. By showing that early ctDNA clearance correlates with improved pathological responses and survival, they have provided oncologists with a practical metric for personalizing treatment. Their findings are now shaping clinical trial designs and moving the field toward more adaptive, biomarker-driven care for NSCLC patients.
Research Focus
Key Achievements
Top Papers
- 1